# Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

> **NCT01822093** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cell Medica Ltd** · enrollment: 8 (actual)

## Conditions studied

- ADV Infection Post Allo-HSCT

## Interventions

- **BIOLOGICAL:** Cytovir-ADV

## Key facts

- **NCT ID:** NCT01822093
- **Lead sponsor:** Cell Medica Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822093, "Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01822093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*